Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care Letter uri icon

Overview

MeSH Major

  • Hematology
  • Leukemia, Myeloid, Acute

publication date

  • December 2017

Research

keywords

  • Letter

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/s41408-017-0018-7

PubMed ID

  • 29238044

Additional Document Info

start page

  • 644

volume

  • 7

number

  • 12